Get the Stockscreener App
9.626
1.17%
0.111
Aligos Therapeutics Inc stock is traded at $9.626, with a volume of 67,185.
It is up +1.17% in the last 24 hours and down -0.61% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$9.515
Open:
$9.52
24h Volume:
67,185
Relative Volume:
0.80
Market Cap:
$59.07M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.3964
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
+21.54%
1M Performance:
-0.61%
6M Performance:
+75.02%
1Y Performance:
-52.95%
1-Day Range:
$9.385
$9.98
1-Week Range:
$8.00
$9.98
52-Week Range:
$3.76
$46.80
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
9.60 | 58.55M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.22 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
781.91 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.37 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.36 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics Stock Rockets 57% With 7-Day Winning Streak - Trefis
Understanding the Setup: (ALGS) and Scalable Risk - news.stocktradersdaily.com
Is Aligos Therapeutics Inc. (5WK0) stock a good hedge against inflationJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
Why Aligos Therapeutics Inc. stock could outperform in 2025Market Growth Summary & AI Optimized Trade Strategies - newser.com
Transcript : Aligos Therapeutics, Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-17-2025 03 - MarketScreener
Is Aligos Therapeutics Inc. stock undervalued vs historical averagesEntry Point & Entry Point Confirmation Alerts - newser.com
What moving averages say about Aligos Therapeutics Inc.2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
How supply shortages influence Aligos Therapeutics Inc. (5WK0) stockTreasury Yields & Weekly Chart Analysis and Trade Guides - newser.com
Can Aligos Therapeutics Inc. (5WK0) stock sustain margin levels2025 Geopolitical Influence & Safe Investment Capital Preservation Plans - newser.com
Will Aligos Therapeutics Inc. (5WK0) stock outperform global peersJuly 2025 Analyst Calls & Short-Term High Return Ideas - newser.com
When is the best time to exit Aligos Therapeutics Inc.July 2025 Earnings & High Win Rate Trade Alerts - newser.com
Is Aligos Therapeutics Inc. (5WK0) stock a buy on weaknessOptions Play & Community Driven Trade Alerts - newser.com
What makes Aligos Therapeutics Inc. (5WK0) stock appealing to growth investorsMarket Performance Recap & Technical Confirmation Trade Alerts - newser.com
How buybacks impact Aligos Therapeutics Inc. stock valueBull Run & Accurate Trade Setup Notifications - newser.com
What is the fair value estimate for Aligos Therapeutics Inc. (5WK0) stock in 2025Chart Signals & AI Enhanced Market Trend Forecasts - newser.com
Will Aligos Therapeutics Inc. benefit from macro trendsJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Can Aligos Therapeutics Inc. (5WK0) stock sustain institutional flowsQuarterly Portfolio Report & Smart Investment Allocation Insights - newser.com
Why Aligos Therapeutics Inc. stock remains on buy listsGlobal Markets & Community Trade Idea Sharing Platform - newser.com
Is Aligos Therapeutics Inc. (5WK0) stock resilient in recession scenariosWeekly Stock Summary & Long-Term Growth Stock Strategies - newser.com
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):